Navigating the Annual IRB Continuing Review: What to Prepare and What Reviewers Look For

IRB approval is not a one-time event. Every research program operating under IRB oversight requires annual continuing review — a formal reassessment of the research to confirm that it continues to meet ethical standards and that the risk-benefit balance remains acceptable. For a retatrutide research program, the continuing review is an annual compliance checkpoint that requires preparation and documentation.

Continuing review is the IRB's mechanism for ongoing oversight of approved research. Federal regulations require that IRBs conduct continuing review at intervals appropriate to the degree of risk — for greater-than-minimal-risk research like a retatrutide program, annual review is the standard.

The continuing review is not a rubber stamp. The IRB is reassessing whether the research should continue, whether the consent document remains adequate, and whether any new information — from your program or from the broader literature — changes the risk-benefit assessment.

The continuing review submission typically includes:

Progress report: A summary of the research to date — how many subjects have been enrolled, how many are currently active, how many have completed or withdrawn, and the current status of the program.

Adverse event summary: A summary of all adverse events that occurred during the review period, including the type, severity, relationship to the study compound, and outcome. This is one of the most closely reviewed elements of the continuing review submission.

Protocol deviation summary: A summary of all protocol deviations that occurred during the review period, including the nature of each deviation, whether it was minor or major, and the corrective action taken.

Updated risk-benefit assessment: A brief assessment of whether the risk-benefit balance of the research has changed since the last review. If new safety data has emerged from the TRIUMPH trials or from other sources, this should be addressed.

Consent document review: Confirmation that the consent document remains current and accurate. If new information has emerged that is relevant to the consent process, the consent document may need to be updated.

Investigator attestation: A signed statement from the Principal Investigator confirming that the research has been conducted in accordance with the approved protocol and that the information in the continuing review submission is accurate.

IRB reviewers conducting a continuing review of a retatrutide program will focus on several key areas:

Adverse event profile. Are the adverse events consistent with what was anticipated in the protocol? Are there any unexpected serious adverse events? Is the adverse event rate within the range that was projected?

Enrollment and retention. Is the program enrolling and retaining subjects as planned? Significant deviation from projected enrollment — either much higher or much lower — may prompt questions.

Protocol compliance. Are deviations being identified, documented, and corrected? A program with no documented deviations is suspicious — it suggests either that the program is not monitoring carefully or that deviations are not being documented.

Consent process. Is the consent process being conducted correctly? Are there any issues with the consent documentation?

New information. Has any new information emerged — from the TRIUMPH trials, from other research, or from your own program — that changes the risk-benefit assessment?

The practices that have the smoothest continuing review processes are the ones that maintain their research records consistently throughout the year — not the ones that scramble to reconstruct records at renewal time. If your adverse event log, deviation log, and enrollment records are current and organized, the continuing review submission is straightforward.

Build the continuing review preparation into your annual calendar. Set a reminder 60 days before your approval anniversary to begin assembling the submission. Give yourself time to review the records, identify any issues, and prepare a complete submission.